Jubilant Pharma completes Triad’s US radiopharmacy acquisition

By: |
New Delhi | September 2, 2017 5:39 PM

Jubilant Life Sciences today said its subsidiary Jubilant Pharma has completed the acquisition of the US radiopharmacy business of Triad Isotopes Inc.

jubilant life sciences, Jubilant Pharma, US radiopharmacy acquisition, Jubilant Pharma acquisitionJubilant Pharma Ltd (JPL), through one of its wholly owned subsidiaries, has successfully completed today the acquisition of the US radiopharmacy business of Triad Isotopes Inc, Jubilant Life Sciences said in a BSE filing.

Jubilant Life Sciences today said its subsidiary Jubilant Pharma has completed the acquisition of the US radiopharmacy business of Triad Isotopes Inc. Triad operates the second largest radiopharmacy network in the US with more than 50 pharmacies. Jubilant Pharma Ltd (JPL), through one of its wholly owned subsidiaries, has successfully completed today the acquisition of the US radiopharmacy business of Triad Isotopes Inc, Jubilant Life Sciences said in a BSE filing. “The acquisition adds significant scale to our niche radiopharmaceutical business in the specialty pharma injectibles segment complementing our strategy of being a leading nuclear medicine player,” the company’s Chairman Shyam S Bhartia and Co-Chairman Hari S Bhartia said.

The acquired radiopharmacies will continue to operate independently under the brand name of Triad Isotopes. The acquisition is funded through JPL’s internal accruals with no increase in debt for Jubilant Life Sciences, the company said.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1ICICI Bank drops home loan rate to 6.7%
2Premier Energies bets on domestic content to add solar module capacity
3Indian Bank to divest ASREC stake